Targeted delivery of CD163 + macrophage-derived small extracellular vesicles via RGD peptides promote vascular regeneration and stabilization after spinal cord injury

Wei Peng,Yong Xie,Yudong Liu,Jiaqi Xu,Feifei Yuan,Chengjun Li,Tian Qin,Hongbin Lu,Chunyue Duan,Jianzhong Hu
DOI: https://doi.org/10.1016/j.jconrel.2023.08.025
IF: 11.467
2023-08-24
Journal of Controlled Release
Abstract:Targeted delivery of small extracellular vesicles (sEVs) with low immunogenicity and fewer undesirable side effects are needed for spinal cord injury (SCI) therapy. Here, we show that RGD (Arg-Gly-Asp) peptide-decorated CD163 + macrophage-derived sEVs can deliver TGF-β to the neovascular endothelial cells of the injured site and improve neurological function after SCI. CD163 + macrophages are M2 macrophages that express TGF-β and are reported to promote angiogenesis and vascular stabilization in various diseases. Enriched TGF-β EVs were crucial in angiogenesis and tissue repair. However, TGF-β also boosts the formation of fibrous or glial scars, detrimental to neurological recovery. Our results found RGD-modified CD163 + sEVs accumulated in the injured region and were taken up by neovascular endothelial cells. Furthermore, RGD-CD163 + sEVs promoted vascular regeneration and stabilization in vitro and in vivo , resulting in substantial functional recovery post-SCI. These data suggest that RGD-CD163 + sEVs may be a potential strategy for treating SCI.
pharmacology & pharmacy,chemistry, multidisciplinary
What problem does this paper attempt to address?